MDACC Study No:2012-0062 ( NCT No: NCT01546038)
Title:A Phase 1B/2 Study to Evaluate the Safety and Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Principal Investigator:Jorge Cortes
Treatment Agent:Cytarabine; Daunorubicin; PF-04449913
Study Status:Open
Study Description:The goal of the screening part of this clinical research study is find the
group that you will be assigned to in the main study.

The goal of the main part of the study is to learn the highest tolerable dose
of PF-04449913 that can be given with chemotherapy to patients with AML or
high-risk MDS and to learn if the study drug can help to control the disease.

PF-04449913 is designed to stop the growth of certain cancer stem cells that
may allow cancer to grow.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:Cytarabine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pfizer, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults